Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DFP 11207

Drug Profile

DFP 11207

Alternative Names: DFP-11207

Latest Information Update: 06 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Delta-Fly Pharma
  • Class Antineoplastics; Small interfering RNA; Small molecules
  • Mechanism of Action Immunomodulators; RNA interference; Thymidylate synthase expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 31 May 2019 Adverse events, efficacy and pharmacokinetics data from a phase-I trial in Solid tumours presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 13 Sep 2018 Delta-Fly Pharma completes a phase I trial in Solid tumours (Late-stage disease, Second-line or greater therapy) in USA (PO) (NCT02171221)
  • 20 Jun 2018 Phase-I development in Solid tumours (Late-stage disease) is ongoing in USA (PO) (NCT02171221) (Delta-Fly Pharma pipeline, June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top